Galena Biopharma Announces Pricing of Registered Direct Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Maxim Group Cuts Price Target on Galena Biopharma (GALE) After Meeting with Management
July 11, 2016 7:30 AM EDTMaxim Group maintained a Buy rating on Galena Biopharma (NASDAQ: GALE), and cut the price target to $2.00 (from $4.00), after meeting with management. The NeuVax study has been discontinued. However, following a recently announced capital raise, Galena is well-funded with $32M in cash to... More
